A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Conditions:   Multiple Myeloma;   Non-Hodgkin Lymphoma;   B-Cell Lymphoma Interventions:   Drug: Tiragolumab;   Drug: Daratumumab;   Drug: Rituximab Sponsor:   Genentech, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials